vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v13i1.921vsp-236Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEКАКИЕ ИММУНОМОДУЛЯТОРЫ НЕОБХОДИМЫ ЧАСТО БОЛЕЮЩИМ ДЕТЯМ? ОТ ПОНИМАНИЯ МЕХАНИЗМОВ ДЕЙСТВИЯ ПРЕПАРАТА К КЛИНИЧЕСКОЙ ЭФФЕКТИВНОСТИWHICH IMMUNOMODULATORS ARE INDICATED TO FREQUENTLY ILL CHILDREN? FROM UNDERSTANDING OF MECHANISMS OF ACTION TO CLINICAL EFFICACYКарауловА. В.KaraulovA. V.

PhD, professor, RAMS cor. member, Head of the Department of Clinical Immunology and Allergology of I.M. Sechenov First Moscow State Medical University

drkaraulov@mail.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation201411012014131Вопросы современной педиатрии119123Copyright © Караулов А.В., 20142014Караулов А.В.Karaulov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/236

В статье проанализированы современные представления о механизмах действия пидотимода ― иммуномодулятора, исследования которого расширяют представления о возможностях регуляции иммунного ответа. Пидотимод представляет собой безопасный иммуномодулятор, эффективный как при профилактическом применении, так и в качестве лечебного средства, что подтверждено результатами контролируемых исследований с участием большого числа пациентов. Разработка новых методов исследования в клинической иммунологии позволила понять механизмы действия препарата in vivo, что, в свою очередь, стимулировало дальнейшее применение пидотимода в педиатрической практике.

The article contains analysis of results of mechanisms of action of immunomodulators. Research focused on one of these compounds — pidotimod. Pidotimod is a safe immunomodulator, which is both efficient in prophylactic use and as a medication in controlled trials with participation of a large number of patients. Pidotimod is ministerial to a faster disappearance of signs at the same time, the drug is capable of intensify functions of immune cells both in vivo and in vitro. The improvement of research methology and acquired knowledge of clinical immunology should be the starting point for new research on pidotimod that stimulate further clinical application for the prevention of acute respiratory tract infection in paediatric age.

пидотимодиммуномодуляторострые респираторные инфекциимеханизмы действияpidotimodimmunomodulatoracute respiratory tract infectionsmechanisms of actionReferencesZemskov A.M., Zemskov V.M., Karaulov A.V. Klinicheskaya immunologiya [Clinical Immunology]. Moscow, GOETAR-Media, 2006. 320 p.Zemskov A.M., Zemskov V.M., Karaulov A.V. Klinicheskaya immunologiya [Clinical Immunology]. Moscow, GOETAR-Media, 2006. 320 p.Kuznetsov V.P., Karaulov A.V. Leukinferon - mechanisms of therapeutic action and tactics immune. Int. J. Immunorehabilitation. 1998; 10: 66–75.Kuznetsov V.P., Karaulov A.V. Leukinferon - mechanisms of therapeutic action and tactics immune. Int. J. Immunorehabilitation. 1998; 10: 66–75.Sil'vestrov V.P., Karaulov A.V. Principles of immunoregulatory therapy of certain diseases of the respiratory system. Ter. arkhiv = Therapeutic archive. 1982; 4: 3–9.Sil'vestrov V.P., Karaulov A.V. Principles of immunoregulatory therapy of certain diseases of the respiratory system. Ter. arkhiv = Therapeutic archive. 1982; 4: 3–9.Sil'vestrov V.P., Karaulov A.V. Antibacterial and immunomodulatory therapy of respiratory diseases. Ter. arkhiv = Therapeutic archive. 1983; 3: 3–9.Sil'vestrov V.P., Karaulov A.V. Antibacterial and immunomodulatory therapy of respiratory diseases. Ter. arkhiv = Therapeutic archive. 1983; 3: 3–9.Karaulov A.V., Kalyuzhin O.V. Immunotropnye preparaty: printsipy primeneniya i klinicheskaya effektivnost' [Immunotropic Drugs: Principles and Application of Clinical Efficacy]. Moscow, MTsFER, 2007. 144 p.Karaulov A.V., Kalyuzhin O.V. Immunotropnye preparaty: printsipy primeneniya i klinicheskaya effektivnost' [Immunotropic Drugs: Principles and Application of Clinical Efficacy]. Moscow, MTsFER, 2007. 144 p.Karaulov A.V., Kalyuzhin O.V. Immunotherapy of infectious diseases: problems and prospects. Ter. arkhiv = Therapeutic archive. 2013; 11: 100–108.Karaulov A.V., Kalyuzhin O.V. Immunotherapy of infectious diseases: problems and prospects. Ter. arkhiv = Therapeutic archive. 2013; 11: 100–108.Karaulov A.V., Likov V.F., Kokushkov D.V. Kombinirovannaya immunokorrektsiya infektsionnykh zabolevanii respiratornogo trakta [Combination Immunotherapy of Infectious Diseases of the Respiratory Tract]. Moscow, 2008. 16 p.Karaulov A.V., Likov V.F., Kokushkov D.V. Kombinirovannaya immunokorrektsiya infektsionnykh zabolevanii respiratornogo trakta [Combination Immunotherapy of Infectious Diseases of the Respiratory Tract]. Moscow, 2008. 16 p.Karaulov A.V., Sokurenko S.I., Klimov E.V. Application immunomodulator IRS 19 with recurrent respiratory diseases. RMZh = Russian medical journal. 2000; 8 (13–14): 552–553.Karaulov A.V., Sokurenko S.I., Klimov E.V. Application immunomodulator IRS 19 with recurrent respiratory diseases. RMZh = Russian medical journal. 2000; 8 (13–14): 552–553.Bulgakova V.A., Balabolkin I.I., Ushakova V.V. Current state of sickly children. Pediatrich. farmakol. = Pediatric pharmacology. 2007; 4 (2): 48–52.Bulgakova V.A., Balabolkin I.I., Ushakova V.V. Current state of sickly children. Pediatrich. farmakol. = Pediatric pharmacology. 2007; 4 (2): 48–52.Namazova L.S., Volkov K.S., Torshkhoeva R.M., Alekseeva A.A. New features therapies sickly children. Pediatrich. farmakol. = Pediatric pharmacology. 2008; 5 (2): 12–20.Namazova L.S., Volkov K.S., Torshkhoeva R.M., Alekseeva A.A. New features therapies sickly children. Pediatrich. farmakol. = Pediatric pharmacology. 2008; 5 (2): 12–20.Karaulov A.V. Comment on the article AS Kolbina, AV Kharcheva "The use of immunostimulants in acute respiratory tract infections in children. Foreign experience - a view from the perspective of evidence-based medicine. Pediatrich. farmakol. = Pediatric pharmacology. 2007; 4: 6–7.Karaulov A.V. Comment on the article AS Kolbina, AV Kharcheva "The use of immunostimulants in acute respiratory tract infections in children. Foreign experience - a view from the perspective of evidence-based medicine. Pediatrich. farmakol. = Pediatric pharmacology. 2007; 4: 6–7.Karaulov A.V., Klimov E.V. Clinical efficacy of bacterial immunomodulators and their effect on humoral and secretory factors sickly children. Pediatriya = Pediatrics. 2001; 4: 86–90.Karaulov A.V., Klimov E.V. Clinical efficacy of bacterial immunomodulators and their effect on humoral and secretory factors sickly children. Pediatriya = Pediatrics. 2001; 4: 86–90.Karaulov A.V. Pidotimod drug - a new effective tool in immunotherapy and immunoprophylaxis of respiratory infections in children. Vopr. sovr. pediatrii = Current pediatrics. 2008; 7 (1): 96–101.Karaulov A.V. Pidotimod drug - a new effective tool in immunotherapy and immunoprophylaxis of respiratory infections in children. Vopr. sovr. pediatrii = Current pediatrics. 2008; 7 (1): 96–101.Karaulov A.V. Safety and efficacy of pidotimoda in acute and chronic bronchitis. Vopr. sovr. pediatrii = Current pediatrics. 2010; 9 (6): 139–144.Karaulov A.V. Safety and efficacy of pidotimoda in acute and chronic bronchitis. Vopr. sovr. pediatrii = Current pediatrics. 2010; 9 (6): 139–144.Karaulov A.V. Whether enhance the immune response of respiratory infections in children with allergic diseases? Data research and their implications for clinical practice. Vopr. sovr. pediatrii = Current pediatrics. 2011; 10 (6): 166–169.Karaulov A.V. Whether enhance the immune response of respiratory infections in children with allergic diseases? Data research and their implications for clinical practice. Vopr. sovr. pediatrii = Current pediatrics. 2011; 10 (6): 166–169.Aivazis V., Hatzimichail A., Papachristou A., Valeri R., Iuga-Donca G. Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections. Minerva Pediatr. 2002; 54: 345–349.Aivazis V., Hatzimichail A., Papachristou A., Valeri R., Iuga-Donca G. Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections. Minerva Pediatr. 2002; 54: 345–349.Huang J.H., Huang X.H., Wang K., Li J.C., Xie X.F., Shen C.L., Li L.J., Zheng Q.S. Bioequivalence evaluation of two formulations of pidotimod using a limited sampling strategy. Biomed. Pharmacother. 2013; 67 (6): 475–480.Huang J.H., Huang X.H., Wang K., Li J.C., Xie X.F., Shen C.L., Li L.J., Zheng Q.S. Bioequivalence evaluation of two formulations of pidotimod using a limited sampling strategy. Biomed. Pharmacother. 2013; 67 (6): 475–480.Carta S., Silvestri M., Rossi G.A. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Italian J. Pediatr. 2013; 39: 29.Carta S., Silvestri M., Rossi G.A. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Italian J. Pediatr. 2013; 39: 29.Anisimova N.Yu., Dolzhikova Yu.M., Kokushkov D.V, Borisova, T.V., Chikileva I.O., Sokurenko S.I., Kiselevskii M.V., Karaulov A.V. Features cytokine profile in patients with bronchial asthma in the acute stage. Sechenovskii vestnik = Sechenov bulletin. 2011; 1 (3) –2(4): 26–30.Anisimova N.Yu., Dolzhikova Yu.M., Kokushkov D.V, Borisova, T.V., Chikileva I.O., Sokurenko S.I., Kiselevskii M.V., Karaulov A.V. Features cytokine profile in patients with bronchial asthma in the acute stage. Sechenovskii vestnik = Sechenov bulletin. 2011; 1 (3) –2(4): 26–30.Yarilin A.A. Immunologiya [Immunology]. Moscow, GOETAR-Media, 2010. 752 p.Yarilin A.A. Immunologiya [Immunology]. Moscow, GOETAR-Media, 2010. 752 p.Chun Y.H., Park J.Y., Lee H., Kim H.S., Won S., Joe H.J., Chung W.J., Yoon J.-S., Kim H.H., Kim J.T., Lee J.S. Rhinovirus-infected epithelial cells produce more IL-8 and RANTES compared with other respiratory viruses allergy. Asthma Immunol. Res. 2013; 5 (4): 216–223.Chun Y.H., Park J.Y., Lee H., Kim H.S., Won S., Joe H.J., Chung W.J., Yoon J.-S., Kim H.H., Kim J.T., Lee J.S. Rhinovirus-infected epithelial cells produce more IL-8 and RANTES compared with other respiratory viruses allergy. Asthma Immunol. Res. 2013; 5 (4): 216–223.Edwards M.R., Bartlett N.W., Hussell T., Openshaw P., Johnston S.L. The microbiology of asthma. Nat. Rev. Microbiol. 2012; 10: 459–471.Edwards M.R., Bartlett N.W., Hussell T., Openshaw P., Johnston S.L. The microbiology of asthma. Nat. Rev. Microbiol. 2012; 10: 459–471.Ling-Xin S. et al. Influence of pidotimod on the IL-16, immunoglobulin and T cell subsets in asthmatic children. J. Clin. Pediatr. 2011; 29 (8).Ling-Xin S. et al. Influence of pidotimod on the IL-16, immunoglobulin and T cell subsets in asthmatic children. J. Clin. Pediatr. 2011; 29 (8).Shuqin Z., Yuan Y. Efficacy of pidotimod in treatment of bronchial asthma in children. Shandong Yiyao. 2010; 50 (8): 74–75.Shuqin Z., Yuan Y. Efficacy of pidotimod in treatment of bronchial asthma in children. Shandong Yiyao. 2010; 50 (8): 74–75.Carta S., Silvestri M., Rossi G.A. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Italian J. Pediatr. 2013; 39: 29.Carta S., Silvestri M., Rossi G.A. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Italian J. Pediatr. 2013; 39: 29.Zuccotti G.V. et al. Immunomodulating activity of Pidotimod in children with Down syndrome. J. Biol. Regul. Homeost. Agents. 2013; 27 (1): 253–258.Zuccotti G.V. et al. Immunomodulating activity of Pidotimod in children with Down syndrome. J. Biol. Regul. Homeost. Agents. 2013; 27 (1): 253–258.Grachev A.N. Geterogennost' i funktsional'naya plastichnost' makrofagov vtorogo tipa aktivatsii. Avtoref. … dis. dokt. biol. nauk [Heterogeneity and Functional Plasticity of Macrophage Activation of the Second Type. Author’s abstract]. Moscow, 1998. 40 p.Grachev A.N. Geterogennost' i funktsional'naya plastichnost' makrofagov vtorogo tipa aktivatsii. Avtoref. … dis. dokt. biol. nauk [Heterogeneity and Functional Plasticity of Macrophage Activation of the Second Type. Author’s abstract]. Moscow, 1998. 40 p.Wang J., Li F., Sun R., Gao X., Wei H., Li L.-J., Tian Z. Bacterial colonization dampens influenza-mediated acute lung injury via induction of M2 alveolar macrophages. Nat. Commun. 2013; 3. Doi: 10.1038/3106Wang J., Li F., Sun R., Gao X., Wei H., Li L.-J., Tian Z. Bacterial colonization dampens influenza-mediated acute lung injury via induction of M2 alveolar macrophages. Nat. Commun. 2013; 3. Doi: 10.1038/3106Capsoni F., Minonzio F., Ongari A.M., Girardello R., Zanussi C. Evaluation of the kinetics of the immunomodulating activity of Pidotimod on human neutrophils. Pharmacol. Res. 1992; 26 (Suppl. 2): 172–173.Capsoni F., Minonzio F., Ongari A.M., Girardello R., Zanussi C. Evaluation of the kinetics of the immunomodulating activity of Pidotimod on human neutrophils. Pharmacol. Res. 1992; 26 (Suppl. 2): 172–173.Taramelli D., Malabarba M.G., Basilico N., Sala G., Mattina R., Cocuzza C. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice. Arzneimittelforschung. 1994; 44 (12A): 1425–1430.Taramelli D., Malabarba M.G., Basilico N., Sala G., Mattina R., Cocuzza C. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice. Arzneimittelforschung. 1994; 44 (12A): 1425–1430.Du X.F., Jiang C.Z., Wu C.F., Won E.K., Choung S.Y. Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression. Arch. Pharm. Res. 2008; 31, (9): 1153–1159.Du X.F., Jiang C.Z., Wu C.F., Won E.K., Choung S.Y. Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression. Arch. Pharm. Res. 2008; 31, (9): 1153–1159.Migliorati G., Nicoletti I., Riccardi C. Immunomodulating activity of pidotimod. Arzneimittelforschung. 1994; 44 (12A): 1421–1424.Migliorati G., Nicoletti I., Riccardi C. Immunomodulating activity of pidotimod. Arzneimittelforschung. 1994; 44 (12A): 1421–1424.Hu X. et al. The detailed analysis of the changes of murine DC induced by thymic peptide pidotimod. Hum. Vacc. & Immunother. 2012; 8 (9): 1250–1258.Hu X. et al. The detailed analysis of the changes of murine DC induced by thymic peptide pidotimod. Hum. Vacc. & Immunother. 2012; 8 (9): 1250–1258.Gourgiotis D., Papandopoulos N.G., Bossios A. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J. Asthma. 2004; 41 (3): 285–287.Gourgiotis D., Papandopoulos N.G., Bossios A. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J. Asthma. 2004; 41 (3): 285–287.Zemskov A.M., Zemskov V.M., Karaulov A.V., Novikova L.A. Klinicheskaya immunologiya i allergologiya [Clinical Immunology and Allergology]. Voronezh, 1997. 160 p.Zemskov A.M., Zemskov V.M., Karaulov A.V., Novikova L.A. Klinicheskaya immunologiya i allergologiya [Clinical Immunology and Allergology]. Voronezh, 1997. 160 p.Karaulov A.V. Immunomodulators: from past to future. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2013; 27 (2): 4–5.Karaulov A.V. Immunomodulators: from past to future. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2013; 27 (2): 4–5.

The authors declare that there are no conflicts of interest present.